


# Victor M. Rivera, M.D., FAAN

- **Distinguished Emeritus Professor of Neurology**  
Baylor College of Medicine

- **Founding Director, Maxine Mesinger MS Comprehensive Care Center**  
Baylor College of Medicine



## CONTACT INFORMATION

Victor M. Rivera, M.D., FAAN  
Baylor Neurology  
Baylor College of Medicine Medical Center, McNair Campus  
7200 Cambridge St., 9th Floor, MS: BCM609  
Houston, Texas 77030

Tel: 713-798-2273  
Email: vrivera@bcm.edu

## PROFESSIONAL STATEMENT

I have been dedicated to neurological care for almost five decades and I have been very fortunate to witness the tremendous progress that has been accomplished in every area of this fascinating field of medicine. My philosophy which as a mentor I have given to my students as part of my legacy, is that we are physicians before we are neurologists therefore we should consider each patient as a tremendously individualized situation. Every person is different due to his or her genetics, metabolic and immunologic design, so there are no general rules to apply in understanding health problems of our patients or in providing a therapeutic program or advise. While evidence-based medicine is a relative guide in decision-making, real clinical common sense and judgment remain the core of that other part of medicine that is art. While I consider a privilege having had the opportunity of taking care of practically every aspect of neurology always trying the best for my patients, MS has always been my principal mission. Due to my professional development I was able to dedicate my full efforts to research, education and care of MS since the late 1980's. The long "Road to the Cure" is hazardous, but there are lights in the horizon. Clinical research will assist fundamentally in the identification of efficacious, efficient and safe new therapies. It is impossible to express our appreciation to the many patients who have participated in studies. They are the real heroes and the navigators to the cure foreseen in the horizon.

All the work and dedication taking care of MS patients is spiritually rewarding considering they have taught us so much (including about ourselves).

## SPECIALITY

- Multiple Sclerosis
- Optic Neuritis
- Demyelinating Diseases

## CERTIFICATION

- American Board of Psychiatry and Neurology, Neurology

## EDUCATION

- M.D., Universidad Nacional Autonoma, Mexico City, Mexico
- Internship, Internal Medicine, Manchester Memorial Hospital, Manchester, Conn.
- Residency, Neurology, Baylor College of Medicine, Houston, Texas

## CONSULT

713-798-8170

## CLINIC LOCATION

Maxine Mesinger MS Comprehensive Care Center  
Neurosensory Building  
6501 Fannin, NB100  
Houston, Texas 77030

## CLINICAL INTERESTS

Multiple sclerosis and demyelinating diseases, cerebral and spinal vascular disorders, general neurology

## PROJECTS

- Enhancing education on MS to peers and patient groups
- Promotion of Study MS Groups and MS patients support groups in Latin America

## BCM HONORS

- 2010 Fulbright & Jaworski LLP Faculty Excellence Award for Teaching and Evaluation
- 2010 Member of the Academy of Distinguished Educators — This award recognizes the educational scholarship of faculty members involved in all of the educational missions of Baylor College of Medicine.

## HONORS & AWARDS

- Life Achievement Award, Consortium of MS Centers.
- Life Achievement Award, National MS Society.
- Emeritus Professor, San Carlos University, Hospital Roosevelt, Guatemala City, Guatemala.
- Honorary Member, Brazilian Committee for MS.
- Honorary Member, National Association of Neurologists of the Mexican Institute of Social Security.
- Honorary Member, Peruvian Committee for Treatment and Research in MS.
- Honorary Member, Venezuelan Neurological Society.
- Professor Cathedra Laboris, University of Monterrey, Mexico.
- Honorary President, LACTRIMS VIII Congress, Lima, Peru, 2014, Latin American Committee for Treatment and Research in MS.
- The Victor Rivera Olmos MS Symposium, Durango, Mexico, 2013, Mexican Academy of Neurology.
- Crystal Obelisk for contribution to Mexican knowledge in MS 2008, Mexican Academy of Neurology.
- Science and Education Award 2006, Mexican Academy of Neurology.
- National Hall of Fame of the National MS Society 2003.
- The Victor Rivera Olmos VII Congress of ANNIMSS, July 21 2000, Puerto Vallarta, Mexico, National Association of Neurologists of the Mexican Institute of Social Security.
- Distinguished Neurologist 1999, Mexican Academy of Neurology.

## GRANTS (FUNDING)

- Access to MS Therapy in the Americas, Latin American Committee for Treatment and Research in MS (LACTRIMS)

## MEMBERSHIPS

- Fellow and senior member, American Academy of Neurology (AAN)
- Founding member (1999); twice President, Latin American Committee for Treatment and Research in Multiple Sclerosis (LACTRIMS)
- Life member, Texas Medical Association

## JOURNAL PUBLICATIONS

1. Rojas JI, Gracia F, Parciak T, Alonso R, Becker J, Trevino-Frenk I, et al. [Core data set for real world data in multiple sclerosis: Customization for Latin America from a global task force recommendation]. Rev Neurol. 2024;78(7):185-97. PMID: 38502167.
2. Román MS, González FM, Bardoneschi L, Herrera Fernández M, Eizaguirre MB, Cáceres F, et al. Contextual factors matter: The role of social support in work-related difficulties and employment status in persons with multiple sclerosis. Sclerosis. 2024;2(1):65-76. DOI: 10.3390/sclerosis2010005.
3. Avila M, Tan Y, Hernandez R, Zuberi H, Rivera VM. Correction to: Multiple sclerosis and neuromyelitis optica spectrum disorder: Onset following acute COVID-19 infection, a case series. Neurol Ther. 2023;12(2):701.

- PMID: 36821074.
4. Avila M, Tan Y, Hernandez R, Zuberi H, Rivera VM. Multiple Sclerosis and neuromyelitis optica spectrum disorder: Onset following acute COVID-19 infection, a case series. *Neurol Ther.* 2023;12(1):319-27. PMID: 36399224.
  5. Rivera VM. Neuromyelitis optica spectrum disorder: Redefining an old disease. Present and future challenges. *J Integr Neurosci.* 2023;22(6):139. PMID: 38176944.
  6. Gracia F, Ramírez D, Parajeles-Vindas A, Díaz A, Díaz de la Fé A, Sánchez NER, et al. Neuromyelitis optica spectrum disorder in Central America and the Caribbean: A multinational clinical characterization study. *Neurol Int.* 2022;14(1):284-93. DOI: 10.3390/neurolint14010023.
  7. Amezcua L, Rivera VM, Vazquez TC, Baezconde-Garbanati L, Langer-Gould A. Health disparities, inequities, and social determinants of health in multiple sclerosis and related disorders in the US: A review. *JAMA Neurol.* 2021;78(12):1515-24. PMID: 34605866.
  8. Cristiano E, Abad P, Becker J, Carra A, Correale J, Flores J, et al. Multiple sclerosis care units in Latin America: Consensus recommendations about its objectives and functioning implementation. *J Neurol Sci.* 2021;429:118072. PMID: 34509134.
  9. Rivera VM, Hamuy F, Rivas V, Gracia F, Rojas JI, Bichuetti DB, et al. Status of the neuromyelitis optica spectrum disorder in Latin America. *Mult Scler Relat Disord.* 2021;53:103083. DOI: <https://doi.org/10.1016/j.msard.2021.103083>.
  10. Rivera VM. Editorial of special issue "Multiple sclerosis: Diagnosis and treatment II". *Biomedicines.* 2021;9(11):. PMID: 34829833.
  11. Rojas JI, Carnero Contentti E, Abad P, Aguayo A, Alonso R, Bauer J, et al. Research priorities in multiple sclerosis in Latin America: A multi-stakeholder call to action to improve patients care: Research priorities in MS in LATAM. *Mult Scler Relat Disord.* 2021;53:103038. PMID: 34090128.
  12. Fisher KS, Cuascut FX, Rivera VM, Hutton GJ. Current advances in pediatric onset multiple sclerosis. *Biomedicines.* 2020;8(4):. PMID: 32231060.
  13. Rivera VM, Gracia F, Diaz A. Therapeutic attitudes towards multiple sclerosis in Central America and the Caribbean facing the SARS-CoV-2 pandemic. *Neurologia.* 2020;35(9):705-6. PMID: 32893070.
  14. Rivera VM. Biosimilar drugs for multiple sclerosis: An unmet international need or a regulatory risk? *Neurol Ther.* 2019;8(2):177-84. PMID: 31313222.
  15. Rivera VM. Multiple sclerosis as a universal disease and the challenges to immigrants in high prevalence countries. *Eur J Neurol.* 2018;25(4):612-3. PMID: 29341368.
  16. Rivera VM. Multiple sclerosis: a global concern with multiple challenges in an era of advanced therapeutic complex molecules and biological medicines. *Biomedicines.* 2018;6(4):. PMID: 30513578.
  17. Rivera VM. Multiple sclerosis: depression and disability are globally shared issues of concern. *Neurol Neuroimmunol Neuroinflamm.* 2018;5(4):12. DOI: 10.20517/2347-8659.2018.16.
  18. Rivera VM, Macias MA. Access and barriers to MS care in Latin America. *Mult Scler J Exp Transl Clin.* 2017;3(1):2055217317700668. DOI: doi:10.1177/2055217317700668.
  19. Rivera VM. Medicinal cannabis: Cultural, societal and regulatory challenges in the Americas. *Ann Forensic Res Anal.* 2017;4(1):1038.
  20. Rivera VM. Multiple Sclerosis in Latin Americans: Genetic Aspects. *Curr Neurol Neurosci Rep.* 2017;17(8):57. PMID: 28639238.
  21. Rivera-Olmos VM, Parra-Bernal MC. [Cannabis: Effects in the central nervous system. Therapeutic, societal and legal consequences]. *Rev Med Inst Mex Seguro Soc.* 2016;54(5):626-34. PMID: 27428345.
  22. Rivera VM, Medina MT, Duron RM, Macias MA. Multiple sclerosis care in Latin America. *Neurology.* 2014;82(18):1660-1. PMID: 24799516.
  23. Macias-Islas MA, Soria-Cedillo IF, Velazquez-Quintana M, Rivera VM, Baca-Muro VI, Lemus-Carmona EA, et al. Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis. *Acta Neurol Belg.* 2013;113(4):415-20. PMID: 23670405.
  24. Rivera VM, Jeffery DR, Weinstock-Guttman B, Bock D, Dangond F. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. *BMC Neurol.* 2013;13:80. PMID: 23841877.
  25. Abad P, Nogales-Gaete J, Rivera V, Cristiano E, Hamuy F, Oehninger C, et al. [LACTRIMS consensus document for the pharmacological treatment of the multiple sclerosis and its clinical variants]. *Rev Neurol.* 2012;55(12):737-48. PMID: 23233142.
  26. Avila-Ornelas J, Avila M, Stosic M, Robles L, Prieto PG, Hutton GJ, et al. The role of postpartum intravenous corticosteroids in the prevention of relapses in multiple sclerosis. *Int J MS Care.* 2011;13(2):91-3. PMID: 24453710.
  27. Rivera VM. Tovaxin for multiple sclerosis. *Expert Opin Biol Ther.* 2011;11(7):961-7. PMID: 21563876.
  28. Stosic M, De Jesus P, McCarthy J, Hutton G, Rivera V. Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab. *Neurology.* 2011;77(5):505-7. PMID: 21775738.
  29. Uitdehaag B, Constantinescu C, Cornelisse P, Jeffery D, Kappos L, Li D, et al. Impact of exposure to interferon

- beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. *Ther Adv Neurol Disord.* 2011;4(1):3-14. PMID: 21339904.
30. Cohen BA, Rivera VM. PRISMS: The story of a pivotal clinical trial series in multiple sclerosis. *Curr Med Res Opin.* 2010;26(4):827-38. PMID: 20121658.
31. Rivera VM. The challenge of follow-on biologics for treatment of multiple sclerosis. *Neurology.* 2010;74(10):864. PMID: 20211915.
32. Rivera VM. Multiple sclerosis in Latin America: Reality and challenge. *Neuroepidemiology.* 2009;32(4):294-5. PMID: 19246934.
33. Cristiano E, Arcega R, Correale J, Gabbay AA, Lander-Delgado R, Macias-Islas MA, et al. [Recommendations for optimising the treatment of multiple sclerosis in Latin America]. *Rev Neurol.* 2007;44(8):494-8. PMID: 17455164.
34. Ordóñez L, Skromne E, Ontaneda D, Rivera VM. Multiphasic disseminated encephalomyelitis, systemic lupus erythematosus and antiphospholipid syndrome. *Clin Neurol Neurosurg.* 2007;109(1):102-5. PMID: 16624483.
35. Rivera-Olmos VM, Avila MC. [Multiple sclerosis in Latin America. Are McDonald's criteria really applicable?]. *Rev Mex Neuroci.* 2007;8(1):49-56.
36. Suárez GA, Hutton GJ, Rivera VM. Optic neuritis: Relation with multiple sclerosis. *Acta Neurol Colomb.* 2007;23:141-6.
37. Suárez GA, Lotze TE, Hutton GJ, Rivera VM. Multiple sclerosis in the pediatric population. *Acta Neurol Colomb.* 2007;23:134-40.
38. Butzkeven H, Chapman J, Cristiano E, Grand'Maison F, Hoffmann M, Izquierdo G, et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. *Mult Scler.* 2006;12(6):769-74. PMID: 17263005.
39. Carra A, Rivera-Olmos V, Arcega R, Gabbai A, Haussen SR, Luetic G, et al. [The treatment of multiple sclerosis in Latin America: Current practice and optimal standards. The findings of a survey among neurologists at an interactive workshop]. *Rev Neurol.* 2006;42(7):399-407. PMID: 16602056.
40. Skromne E, Rivera VM, Ontaneda D, Ordóñez L. Progression of progressive multifocal leukoencephalopathy despite treatment with beta-interferon. *Neurology.* 2006;66(11):1787-8; author reply 1787-8. PMID: 16769975.
41. Rivera VM. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. *Neurology.* 2005;64(12):2163. PMID: 15985607.
42. Rivera VM. Modafinil for the treatment of diminished responsiveness in a patient recovering from brain surgery. *Brain Inj.* 2005;19(9):725-7. PMID: 16195186.
43. Rivera VM. The terms Latino and Anglo and tendency to early Alzheimer disease. *Arch Neurol.* 2005;62(11):1787; author reply 1787-8. PMID: 16286562.
44. Rivera-Olmos VM, Lozano JA. [Cogan's syndrome: Neurological manifestations. Case report and review of literature]. *Rev Mex Neuroci.* 2005;6(1):97-101.
45. Cohen BA, Khan O, Jeffery DR, Bashir K, Rizvi SA, Fox EJ, et al. Identifying and treating patients with suboptimal responses. *Neurology.* 2004;63(12 Suppl 6):S33-40. PMID: 15623669.
46. Hong J, Zang YC, Hutton G, Rivera VM, Zhang JZ. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. *J Neuroimmunol.* 2004;152(1-2):126-39. PMID: 15223245.
47. Hong J, Zang YC, Li S, Rivera VM, Zhang JZ. Ex vivo detection of myelin basic protein-reactive T cells in multiple sclerosis and controls using specific TCR oligonucleotide probes. *Eur J Immunol.* 2004;34(3):870-81. PMID: 14991617.
48. Rivera VM. Esclerosis multiple: evidencias, genericos y similares. *Rev Mex Neuroci.* 2004;5(4):286-7.
49. Rivera-Olmos VM, Hutton GJ, Breitbach WT. Discrepancia entre clínica e imagen: Esclerosis múltiple en fase intermedia. Presentación de un caso y revisión del tema [Discrepancy between clinics and image techniques: Intermediate phase of multiple sclerosis. A case report and review of the literature]. *Rev Mex Neuroci.* 2004;5(2):158-62.
50. Zang YC, Li S, Rivera VM, Hong J, Robinson RR, Breitbach WT, et al. Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis. *J Immunol.* 2004;172(8):5120-7. PMID: 15067096.
51. Zang YC, Skinner SM, Robinson RR, Li S, Rivera VM, Hutton GJ, et al. Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis. *Mult Scler.* 2004;10(5):499-506. PMID: 15471364.
52. Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, et al. The utility of MRI in suspected MS: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology.* 2003;61(5):602-11. PMID: 12963748.
53. Frohman TC, Frohman EM, O'Suilleabhain P, Salter A, Dewey RB, Jr, et al. Accuracy of clinical detection of INO in MS: corroboration with quantitative infrared oculography. *Neurology.* 2003;61(6):848-50. PMID: 14504338.
54. Rivera VM. [Deciding on treatment in multiple sclerosis]. *Rev Neurol.* 2003;36(1):80-5. PMID: 12577220.

55. Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Zhang JZ. Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis. *Ann Neurol.* 2003;53(2):189-97. PMID: 12557285.
56. Velazquez-Quintana M, Macias-Islas MA, Rivera-Olmos V, Lozano-Zarate J. [Multiple sclerosis in Mexico: A multicentre study]. *Rev Neurol.* 2003;36(11):1019-22. PMID: 12808495.
57. Zang Y, Hong J, Robinson R, Li S, Rivera VM, Zhang JZ. Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis. *J Neuroimmunol.* 2003;137(1-2):144-53. PMID: 12667659.
58. Zang YC, Hong J, Rivera VM, Killian J, Zhang JZ. Human anti-idiotypic T cells induced by TCR peptides corresponding to a common CDR3 sequence motif in myelin basic protein-reactive T cells. *Int Immunol.* 2003;15(9):1073-80. PMID: 12917259.
59. Hong J, Tejada-Simon MV, Rivera VM, Zang YC, Zhang JZ. Anti-viral properties of interferon beta treatment in patients with multiple sclerosis. *Mult Scler.* 2002;8(3):237-42. PMID: 12120696.
60. Rivera VM. II Congreso de LACTRIMS. *Rev Neurol.* 2002;35(12):1175-6.
61. Tejada-Simon MV, Hong J, Rivera VM, Zhang JZ. Skewed autoantibody reactivity to the extracellular domain of myelin oligodendrocyte glycoprotein in multiple sclerosis. *Immunology.* 2002;107(4):403-10. PMID: 12460184.
62. Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Killian JM, Zhang JZ. Detection of viral DNA and immune responses to the human herpesvirus 6 101-kilodalton virion protein in patients with multiple sclerosis and in controls. *J Virol.* 2002;76(12):6147-54. PMID: 12021348.
63. Zang YC, Halder JB, Hong J, Rivera VM, Zhang JZ. Regulatory effects of estriol on T cell migration and cytokine profile: inhibition of transcription factor NF-kappa B. *J Neuroimmunol.* 2002;124(1-2):106-14. PMID: 11958828.
64. Zhang JZ, Rivera VM, Tejada-Simon MV, Yang D, Hong J, Li S, et al. T cell vaccination in multiple sclerosis: Results of a preliminary study. *J Neurol.* 2002;249(2):212-8. PMID: 11985389.
65. Ciancio SJ, Mutchnik SE, Rivera VM, Boone TB. Urodynamic pattern changes in multiple sclerosis. *Urology.* 2001;57(2):239-45. PMID: 11182328.
66. Rivera VM, Cabrera JA. Aboriginals with multiple sclerosis: HLA types and predominance of neuromyelitis optica. *Neurology.* 2001;57(5):937-8. PMID: 11552042.
67. Rivera VM. [Neuroimaging in multiple sclerosis]. *Rev Neurol.* 2001;32(3):283-5. PMID: 11310287.
68. Rivera VM. [Pharmacologic treatment of multiple sclerosis]. *Rev Neurol.* 2001;32(3):285-8. PMID: 11310288.
69. Rivera VM. La decada del cerebro. *Neurociencia.* 2001;2(13):131.
70. Tejada-Simon MV, Hong J, Rivera VM, Zhang JZ. Reactivity pattern and cytokine profile of T cells primed by myelin peptides in multiple sclerosis and healthy individuals. *Eur J Immunol.* 2001;31(3):907-17. PMID: 11241296.
71. Zang YC, Halder JB, Samanta AK, Hong J, Rivera VM, Zhang JZ. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta. *J Neuroimmunol.* 2001;112(1-2):174-80. PMID: 11108946.
72. Hong J, Zang YC, Tejada-Simon MV, Li S, Rivera VM, Killian J, et al. Reactivity and regulatory properties of human anti-idiotypic antibodies induced by T cell vaccination. *J Immunol.* 2000;165(12):6858-64. PMID: 11120809.
73. Rivera VM, Cabrera JA. La Esclerosis Multiple en Latino America. *MEDICO Interamericano.* 2000;19(10):458-65.
74. Rivera VM. [The treatment of multiple sclerosis with beta-interferon 1a]. *Rev Neurol.* 2000;31(5):470-1. PMID: 11027100.
75. Rivera VM. Grupo de Estudio de EM (Mexico): Uso de Agentes Modificadores de la Enfermedad. *Neurociencia.* 2000;3:29-30.
76. Rivera VM. Introduccion al Simposio Latino Americano. *Rev Neurol.* 2000;31(5):469.
77. Tejada-Simon MV, Zang YC, Yang D, Hong J, Li S, Singh RA, et al. Aberrant T cell responses to myelin antigens during clinical exacerbation in patients with multiple sclerosis. *Int Immunol.* 2000;12(12):1641-50. PMID: 11099303.
78. Zang YC, Hong J, Rivera VM, Killian J, Zhang JZ. Preferential recognition of TCR hypervariable regions by human anti-idiotypic T cells induced by T cell vaccination. *J Immunol.* 2000;164(8):4011-7. PMID: 10754292.
79. Zang YC, Hong J, Tejada-Simon MV, Li S, Rivera VM, Killian JM, et al. Th2 immune regulation induced by T cell vaccination in patients with multiple sclerosis. *Eur J Immunol.* 2000;30(3):908-13. PMID: 10741408.
80. Zang YC, Samanta AK, Halder JB, Hong J, Tejada-Simon MV, Rivera VM, et al. Aberrant T cell migration toward RANTES and MIP-1 alpha in patients with multiple sclerosis. Overexpression of chemokine receptor CCR5. *Brain.* 2000;123 ( Pt 9):1874-82. PMID: 10960051.
81. Zang YC, Yang D, Hong J, Tejada-Simon MV, Rivera VM, Zhang JZ. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS. *Neurology.* 2000;55(3):397-404. PMID: 10932275.
82. Hong J, Zang YC, Tejada-Simon MV, Kozovska M, Li S, Singh RA, et al. A common TCR V-D-J sequence in V

- beta 13.1 T cells recognizing an immunodominant peptide of myelin basic protein in multiple sclerosis. *J Immunol.* 1999;163(6):3530-8. PMID: 10477628.
83. Kil K, Zang YC, Yang D, Markowski J, Fuoco GS, Vendetti GC, et al. T cell responses to myelin basic protein in patients with spinal cord injury and multiple sclerosis. *J Neuroimmunol.* 1999;98(2):201-7. PMID: 10430053.
84. Kozovska ME, Hong J, Zang YC, Li S, Rivera VM, Killian JM, et al. Interferon beta induces T-helper 2 immune deviation in MS. *Neurology.* 1999;53(8):1692-7. PMID: 10563614.
85. Singh RA, Zang YC, Shrivastava A, Hong J, Wang GT, Li S, et al. Th1 and Th2 deviation of myelin-autoreactive T cells by altered peptide ligands is associated with reciprocal regulation of Lck, Fyn, and ZAP-70. *J Immunol.* 1999;163(12):6393-402. PMID: 10586029.
86. Zang YC, Kozovska MM, Hong J, Li S, Mann S, Killian JM, et al. Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis. *Eur J Immunol.* 1999;29(5):1692-700. PMID: 10359124.
87. Kozovska M, Zang YC, Aebsicher I, Lnu S, Rivera VM, Crowe PD, et al. T cell recognition motifs of an immunodominant peptide of myelin basic protein in patients with multiple sclerosis: Structural requirements and clinical implications. *Eur J Immunol.* 1998;28(6):1894-901. PMID: 9645371.
88. Zang YC, Kozovska M, Aebsicher I, Li S, Boehme S, Crowe P, et al. Restricted TCR Valpha gene rearrangements in T cells recognizing an immunodominant peptide of myelin basic protein in DR2 patients with multiple sclerosis. *Int Immunol.* 1998;10(7):991-8. PMID: 9701037.
89. Jerger J, Alford B, Lew H, Rivera V, Chmiel R. Dichotic listening, event-related potentials, and interhemispheric transfer in the elderly. *Ear Hear.* 1995;16(5):482-98. PMID: 8654903.
90. Trujillo JR, Garcia-Ramos G, Novak IS, Rivera VM, Huerta E, Essex M. Neurologic manifestations of AIDS: A comparative study of two populations from Mexico and the United States. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1995;8(1):23-9. PMID: 8548343.
91. Safi HJ, Bartoli S, Hess KR, Shenaq SS, Viets JR, Butt GR, et al. Neurologic deficit in patients at high risk with thoracoabdominal aortic aneurysms: The role of cerebral spinal fluid drainage and distal aortic perfusion. *J Vasc Surg.* 1994;20(3):434-44; discussion 442-3. PMID: 8084037.
92. Crawford ES, Svensson LG, Hess KR, Shenaq SS, Coselli JS, Safi HJ, et al. A prospective randomized study of cerebrospinal fluid drainage to prevent paraplegia after high-risk surgery on the thoracoabdominal aorta. *J Vasc Surg.* 1991;13(1):36-45; discussion 45-6. PMID: 1987395.
93. Mawad ME, Rivera V, Crawford S, Ramirez A, Breitbach W. Spinal cord ischemia after resection of thoracoabdominal aortic aneurysms: MR findings in 24 patients. *AJNR Am J Neuroradiol.* 1990;11(5):987-91. PMID: 2121005.
94. Mawad ME, Rivera V, Crawford S, Ramirez A, Breitbach W. Spinal cord ischemia after resection of thoracoabdominal aortic aneurysms: MR findings in 24 patients. *AJR Am J Roentgenol.* 1990;155(6):1303-7. PMID: 2122684.
95. Rivera VM. Safety of intrathecal steroids in multiple sclerosis. *Arch Neurol.* 1989;46(7):718-9. PMID: 2535600.
96. Olmos Garcia de Alba G, Gamboa Marrufo JD, Rengifo Ramos O, Calderon FE, Espinosa Tanguna R, Rivera Olmos VM, et al. Rett's syndrome with Lennox-Gastaut pattern. *Clin Electroencephalogr.* 1987;18(4):187-90. PMID: 3117441.
97. Jerger JF, Oliver TA, Chmiel RA, Rivera VM. Patterns of auditory abnormality in multiple sclerosis. *Audiology.* 1986;25(4-5):193-209. PMID: 3566629.
98. Rivera VM, Meyer JS, Hata T, Ishikawa Y, Imai A. Narcolepsy following cerebral hypoxic ischemia. *Ann Neurol.* 1986;19(5):505-8. PMID: 3717910.
99. Rivera VM. Multiple sclerosis. Is the mystery beginning to unfold? *Postgrad Med.* 1986;79(8):217-32. PMID: 3520524.
100. Rivera VM. Stroke. A guide to differential diagnosis and prevention. *Postgrad Med.* 1985;77(4):81-8. PMID: 3975191.
101. Hannley M, Jerger JF, Rivera VM. Relationships among auditory brain stem responses, masking level differences and the acoustic reflex in multiple sclerosis. *Audiology.* 1983;22(1):20-33. PMID: 6830528.
102. Jerger J, Hannley M, Rivera V. Auditory brainstem response and the masking level difference. *Ann N Y Acad Sci.* 1982;388:466-70. PMID: 6953883.
103. Rivera VM. Intrap spinal steroid therapy. *Neurology.* 1981;31(8):1060-1. PMID: 6894967.
104. Rivera VM, Grabois M, Deaton W, Breitbach W, Hines M. Modified snake venom in amyotrophic lateral sclerosis. Lack of clinical effectiveness. *Arch Neurol.* 1980;37(4):201-3. PMID: 7362484.
105. Jankovic J, Rivera VM. Hereditary myoclonus and progressive distal muscular atrophy. *Ann Neurol.* 1979;6(3):227-31. PMID: 534421.
106. Jankovic J, Rivera V. Hereditary myoclonus and progressive muscular atrophy: A new syndrome. *Trans Am Neurol Assoc.* 1978;103:116-8. PMID: 757033.
107. Jankovic J, Rivera VM. Hereditary myoclonus and progressive spinal muscular atrophy: A new syndrome. *Ann Neurol.* 1978;4(2):170-1.

108. Perez FI, Hruska NA, Stell RL, Rivera VM. Computerized assessment of memory performance in dementia. *Can J Neurol Sci.* 1978;5(3):307-12. PMID: 359117.
109. Rivera VM, Patten BM. Neuromyopathy in malignant hyperthermia. *J Clin Psychiatry.* 1978;39(1):67-71. PMID: 580262.
110. Rivera VM. Acute hypokalemic myopathy in alcoholism. *Arch Neurol.* 1978;35(9):619. PMID: 687190.
111. Guido EM, Rivera VM. Precordialgia as a manifestation of vertebrobasilar insufficiency. *J Am Geriatr Soc.* 1977;25(10):463-5. PMID: 903546.
112. Rivera VM. Viruses and multiple sclerosis. *Jama.* 1977;238(12):1247. PMID: 578169.
113. Rodriguez J, Rivera VM. Risk factors in stroke in a Mexican-American population (Houston). *Neurol Neurocir Psiquiatr.* 1977;18(2-3 Suppl):225-34. PMID: 616532.
114. Rivera VM. Letter: Symptomatic care of patients with amyotrophic lateral sclerosis. *Jama.* 1976;235(24):2584-5. PMID: 946858.
115. Perez FI, Gay JR, Taylor RL, Rivera VM. Patterns of memory performance in the neurologically impaired aged. *Can J Neurol Sci.* 1975;2(4):347-55. PMID: 1201525.
116. Perez FI, Rivera VM, Meyer JS, Gay JR, Taylor RL, Mathew NT. Analysis of intellectual and cognitive performance in patients with multi-infarct dementia, vertebrobasilar insufficiency with dementia, and Alzheimer's disease. *J Neurol Neurosurg Psychiatry.* 1975;38(6):533-40. PMID: 1151420.
117. Rivera VM, Breitbach WB, Swanke L. Letter: Dantrolene in amyotrophic lateral sclerosis. *Jama.* 1975;233(8):863-4. PMID: 1173890.
118. Rivera VM, Keichian AH, Oliver RE. Persistent parkinsonism following neuroleptanalgesia. *Anesthesiology.* 1975;42(5):635-7. PMID: 1130732.
119. Meyer JS, Bauer RB, Rivera-Olmos VM, Nolan DC, Lerner AM. Herpesvirus hominis encephalitis. Neurological manifestations and use of idoxuridine. *Arch Neurol.* 1970;23(5):438-50. PMID: 4319497.

## BOOKS and VOLUMES

1. Rivera VM, editor. *Multiple sclerosis: Diagnosis and treatment II.* Basel, Switzerland: MDPI; 2022.
2. Olmos García de Alba G, Rivera Olmos VM, Gamboa Marrufo JD, editors. *Aspectos clínicos de neurología pediátrica.* Mexico: Editorial Trillas; 1990. p. 335.

## BOOK CHAPTERS and OTHER PUBLICATIONS

1. Rivera VM. Proemio. Por los surcos del olvido. In: Ramos Zúñiga R, editor. *Los sinuosos caminos de la demencia.* Guadalajara, México: Editorial Universitaria; 2015.
2. Rivera VM. Prologue. In: D'Onghia A, Molina O, editors. *Esclerosis múltiple. Diagnóstico y tratamiento.* 6th ed. Caracas, Venezuela: VECTRIMS; 2015.
3. Rivera VM. Prologue. In: Fernanda Oyuela Medina M, editor. *Y en su silencio escuché su voz.* Tegucigalpa: Editorial Universitaria, Universidad Nacional Autónoma de Honduras; 2015.
4. Rivera VM. Terapias futuras. In: D'Onghia A, Molina O, editors. *Esclerosis múltiple. Diagnóstico y tratamiento.* 6th ed. Caracas, Venezuela: VECTRIMS; 2015.
5. Rivera VM. Prologue. In: Abad Herrera P, Correale J, Barahona J, editors. *Esclerosis múltiple (Para el médico en la práctica diaria).* Ecuador: PLM; 2014.
6. Rivera VM. Spinal stroke. In: Aminoff MJ, Daroff RB, editors. *Encyclopedia of the neurological sciences.* 2nd ed. Vol. 4. Oxford: Academic Press; 2014. p. 288.
7. Rivera Olmos VM. Biomarcadores en la esclerosis múltiple. In: Macías Islas MA, editor. *Diagnóstico de la esclerosis múltiple. Sistema de actualización médica en esclerosis múltiple.* México DF: Intersistemas S.A. and C.V.; 2013.
8. Rivera VM. Prologue. In: Ruiz Peraza M, Adelita Reyes-Velarde M, editors. *Abriendo caminos, mi vida y la esclerosis múltiple.* Spain: Bubok Editorial; 2013.
9. Rivera Olmos VM. Estructura y efecto clínico inmunomolecular del inf-β-1b. In: Orozco N, García Velázquez L, editors. *Interferon β-1b. Evidencia vs experiencia-2012-esclerosis múltiple.* Barcelona: Publicaciones Permanyer; 2012.
10. Rivera VM. Prologue. In: VECTRIMS , editor. *Guías para el diagnóstico y tratamiento de la esclerosis múltiple.* 5th ed. Caracas, Venezuela: Sociedad Venezolana de Neurología; 2012.
11. Rivera Olmos VM. Prefacio. In: Macías Islas MA, editor. *Daño cognitivo en esclerosis múltiple.* México: Editorial Médica Panamericana; 2010.
12. Rivera VM. El diagnóstico de esclerosis múltiple y sus retos en Latinoamérica. In: Corona T, de Jesús Flores J, editors. *Esclerosis múltiple.* Mexico City: Editorial Médica Panamericana; 2010.
13. Rivera VM. Impacto social. In: Cuevas García CF, editor. *Esclerosis múltiple. Manual para médicos no*

- neurólogos. Mexico City: PyDesa; 2010.
14. Rivera VM. Prólogo. In: Cuevas García CF, editor. Esclerosis múltiple. Manual para médicos no neurólogos. Mexico City: PyDesa; 2010.
  15. Rivera VM. Prólogo. In: Adelita Reyes-Velarde M, editor. Con los pies en la tierra. Viviendo con la esclerosis múltiple. 3rd ed. North America & International: Trafford Publishing; 2009.
  16. Rivera VM. Prólogo. In: VECTRIMS , editor. Pautas para el diagnóstico y tratamiento de la esclerosis múltiple. 4th ed. Caracas, Venezuela: Sociedad Venezolana de Neurología; 2009.
  17. Rivera VM, Skromne E. Esclerosis múltiple. In: Halabe Cherem J, editor. Vacunación en el adulto. Mexico City: McGraw Hill; 2008.
  18. Rivera Olmos VM. La genética de la esclerosis múltiple. Aspectos regionales y raciales. In: Cuevas García CF, editor. Fronteras en la esclerosis múltiple. Mexico City: Planeación y Desarrollo Editorial, S.A. de C.V.; 2007.
  19. Rivera-Olmos VM, Skromne Eisenberg E, Ordoñez Boschetti L. Historia natural, clasificación, variedades clínicas y escalas de evaluación de la esclerosis múltiple. In: Cuevas García CF, editor. Fronteras en la esclerosis múltiple. Mexico City: Planeación y Desarrollo Editorial, S.A. de C.V.; 2007.
  20. Rivera VM. Prefacio. In: Ruiz Peraza JM, editor. ¡... Y es bello vivir! Cienfuegos, Cuba: Ediciones Mecenas; 2005.
  21. Rivera VM. Apresentação. In: Roberto Haussen S, editor. Esclerose múltipla. Informações científicas para o leigo. Porto Alegre, RS, Brasil: Editora Concito; 2004.
  22. Rivera VM. Presentación. In: Oehninger Gatti C, editor. Esclerosis múltiple: Nuevos conceptos etiopatogénicos. Fundamentos diagnósticos y terapéuticos. Montevideo: ARENA; 2004.
  23. Rivera VM. Prologo. In: Nuñez L, editor. El manejo integral de los pacientes con esclerosis múltiple. 2nd ed. Mexico City: AMMEEM; 2003.
  24. Rivera VM. Spinal stroke. In: Aminoff MJ, Daroff RB, editors. Encyclopedia of the neurological sciences. Vol. 4. San Diego: Academic Press; 2003. p. 375-376.
  25. Rivera VM. Tratamiento immunomodulador. In: Nuñez L, editor. El manejo integral de los pacientes con esclerosis múltiple. 2nd ed. Mexico City: AMMEEM; 2003.
  26. Rivera VM. Prefacio. In: Garcia Guerra CM, editor. Apuntes de neurología clínica. Chihuahua, Mexico: Gobierno del Estado de Chihuahua; 2002.
  27. Rivera VM. Prologo. In: Arriagada C, Nogales-Gaete J, editors. Esclerosis múltiple: Una mirada ibero-panamericana. Santiago, Chile: Arrynnog ediciones; 2002.
  28. Olmos Garcia de Alba G, Rivera VM. Aspectos legales de la epilepsia. In: Feria Velasco A, Martinez de Munoz D, Rubio Donnadieu F, editors. Epilepsia. Mexico, D.F.: INNN; 1997.
  29. Rivera VM. Corticosteroids in acute stroke. In: Welch KMA, Caplan LR, Reis DJ, Sies Jö BK, Weir B, editors. Primer on cerebrovascular diseases. San Diego: Academic Press; 1997.
  30. Rivera VM. Spinal stroke. In: Welch KMA, Caplan LR, Reis DJ, Sies Jö BK, Weir B, editors. Primer on cerebrovascular diseases. San Diego: Academic Press; 1997.
  31. Zhang J, Rivera VM, Raus J, Steinman L. New treatments for multiple sclerosis. In: Appel SH, editor. Current neurology. Vol. 17. Netherlands: IOS Press; 1997.
  32. Rivera VM. Diagramas de decisión médica. In: Olivares L, Nunez L, editors. Algoritmos. Mexico: Editorial Trillas; 1990. p. 110-154.
  33. Rivera VM. Enfermedades bacterianas del sistema nervioso central; manejo a distintas edades. In: Olmos García de Alba G, Rivera Olmos VM, Gamboa Marrufo JD, editors. Aspectos clínicos de neurología pediátrica. Mexico: Editorial Trillas; 1990. p. 195-198.
  34. Rivera VM. Enfermedades infecciosas relacionadas con torch. In: Olmos García de Alba G, Rivera Olmos VM, Gamboa Marrufo JD, editors. Aspectos clínicos de neurología pediátrica. Mexico: Editorial Trillas; 1990. p. 207-213.
  35. Rivera VM. Enfermedades sistémicas desmielinizantes y progresivas. In: Olmos García de Alba G, Rivera Olmos VM, Gamboa Marrufo JD, editors. Aspectos clínicos de neurología pediátrica. Mexico: Editorial Trillas; 1990. p. 53-57.
  36. Rivera VM. Epilepsia en edad escolar. In: Olmos García de Alba G, Rivera Olmos VM, Gamboa Marrufo JD, editors. Aspectos clínicos de neurología pediátrica. Mexico: Editorial Trillas; 1990. p. 300-305.
  37. Rivera VM. Errores congénitos del metabolismo. In: Olmos García de Alba G, Rivera Olmos VM, Gamboa Marrufo JD, editors. Aspectos clínicos de neurología pediátrica. Mexico: Editorial Trillas; 1990. p. 32-35.
  38. Rivera VM. Panencefalitis esclerosante subaguda. In: Olmos García de Alba G, Rivera Olmos VM, Gamboa Marrufo JD, editors. Aspectos clínicos de neurología pediátrica. Mexico: Editorial Trillas; 1990. p. 218-221.
  39. Perez FI, Brown GA, Rusin MJ, Koehler D, Rivera VM. Computer as a prosthesis in neuropsychological rehabilitation of stroke patients. In: Piehot P, Berner P, Wolf R, Thau K, editors. Psychiatry. Vol. 2. Plenum Publishing Corporation; 1985.
  40. Rivera VM, Ravichandran GR, Perez FI, Breitbach W, Wulff E, Grajeda F. Neuropsychological aspects in cortical blindness due to cerebral infarcts. In: Piehot P, Berner P, Wolf R, Thau K, editors. Psychiatry. Vol. 2. Plenum Publishing Corporation; 1985.

41. Rivera VM, Wulff EA, Breitbach WT. Clinical aspects and management of mitral valve prolapse in patients with multiple sclerosis. In: Pedersen E, Clausen J, Oades L, editors. Actual problems in multiple sclerosis research. Copenhagen: FADL's Forlag; 1983. p. 197-200.
42. Rivera VM. Neurological disorders of the newborn. In: Olmos García de Alba G, editor. Neurodiagnostic procedures in the newborn. Ediciones Medicas del Hospital Infantil de Mexico; 1983. p. 17-29.
43. Wulff EA, Rivera VM, Breitbach WT. Head bobbing in multiple sclerosis. In: Pedersen E, Clausen J, Oades L, editors. Actual problems in multiple sclerosis research. Copenhagen: FADL's Forlag; 1983. p. 193-196.
44. Rivera VM, Wulff E, Breitbach W, Huston D. Chronic low dose immunosuppression in multiple sclerosis. In: Hommes OR, Martin J, Tourtelotte WW, editors. Immunotherapies in multiple sclerosis. Proceedings of a Workshop on Immunosuppressive Treatment of Multiple Sclerosis. (Nijmegen, The Netherlands, June 1982). Suffolk, England: Stuart Phillips; 1982.
45. Rivera VM. Pharmacological and surgical modalities (commentary). In: Mulder DW, editor. The diagnosis and treatment of amyotrophic lateral sclerosis. Boston: Houghton Mifflin Professional Publishers; 1980.
46. Rivera VM. Respiratory problems (commentary). In: Mulder DW, editor. The diagnosis and treatment of amyotrophic lateral sclerosis. Boston: Houghton Mifflin Professional Publishers; 1980.
47. Perez FI, Brown GA, Yonovitz A, Lee DM, Rivera VM. Rehabilitation of a right hemisphere stroke patient exhibiting auditory extinction: Computerized behavioral approach. In: Meyer JS, Lechner H, Reivich M, editors. Cerebral vascular disease 2. 9th Salzburg Conference, 1978. Amsterdam Oxford: Excerpta Medica; 1979.
48. Rivera VM, Perez FI, Cooke NA, Hruskan NA. Computerized assessment of memory performance in patients with unilateral stroke. In: Meyer JS, Lechner H, Reivich M, editors. Cerebral vascular disease 2. 9th Salzburg Conference, 1978. Amsterdam Oxford: Excerpta Medica; 1979.
49. Baer PE, Faibis GM, Meyer JS, Mathew NT, Rivera VM. Neuropsychological correlates of hemispheric and regional blood flow in dementia. In: Meyer JS, Lechner H, Reivich M, editors. Cerebral vascular disease. 7th International Conference. Salzburg, 1974. Stuttgart: Gerog Thieme; 1976.
50. Rivera VM, Meyer JS, Baer PE, Faibis GM. Vertebrobasilar insufficiency as a cause of dementia. Controlled therapeutic trial with betahistine HCL. In: Meyer JS, Lechner H, Reivich M, editors. Cerebral vascular disease. 7th International Conference. Salzburg, 1974. Stuttgart: Gerog Thieme; 1976.
51. Rivera VM, Meyer JS. Dementia and cerebrovascular disease. In: Meyer JS, editor. Modern concepts of cerebrovascular disease. Holliswood, NY: Spectrum Publications; 1975.

## POSTER and PLATFORM PRESENTATIONS

1. Alonso RN, Rivera V, Carnero Contentti EG, Hamuy Diaz de Bedoya VF, Ciampi E, Silva B, et al. Recommendations on NMOSD treatment in Latin America: Consensus-based RAND/UCLA methodology. Mult Scler. 2023;29(3S):948-9.
2. Patricio Correa E, Piedra Andrade JS, Carnero Contentti EG, Torres G, Barrera Madera RA, Ortiz Yepez A, et al. Development of a questionnaire to measure quality of life in neuromyelitis optica spectrum disorder patients. A validation study from Latin America. Mult Scler. 2023;29(3S):666-7.
3. Rivera V, Repovic P, Adeyemi A, Altincatal A, Perez-Bajandas C, Saldana-King T, et al. Sociodemographic and clinical characteristics of patients with multiple sclerosis by race and ethnicity (NARCRMS Registry). Neurology. 2021;96(15 Suppl):1703.
4. Rivera V. The reality of MS epidemiology in LATAM. Mult Scler J. 2021;27(1 suppl):6-7. [Oral Presentation]
5. Rivera V, Repovic P, Adeyemi A, Altincatal A, Perez-Bajandas C, Saldana-King T, et al. Socio-demographic and clinical characteristics of patients with multiple sclerosis by race and ethnicity (NARCRMS registry). Mult Scler. 2020; 26(S3):354.
6. Stosic M, De Jesus P, McCarthy J, Hutton GJ, Rivera VM. Multiple sclerosis patient treated with natalizumab develops immune thrombocytopenic purpura. Presented at the Baylor College of Medicine (BCM), Current Neurology 2012 in Houston, Texas (Nov. 3-4, 2012).
7. Avila M, Prieto P, Avila-Ornelas J, Stosic M, Amin A, Hutton GJ, et al. Distal limb discoloration in patients with multiple sclerosis - Case series of 41 patients. Neurology. 2011;76(Suppl 4):A290.
8. Avila J, Avila M, Stosic M, Robles L, Prieto PG, Hutton GJ, et al. The role of postpartum intravenous corticosteroids in the prevention of relapses in multiple sclerosis. Int J MS Care. 2010;12 Suppl 1:13.
9. Avila M, Hutton G, Rivera VM. Recurrent and multiphasic disseminated encephalomyelitis, case series. Int J MS Care. 2010;12 Suppl 1:14.
10. Avila M, Prieto P, Robles L, Avila J, Stosic M, Hutton G, et al. Distal lower limb discoloration in patients with multiple sclerosis. Int J MS Care. 2010;12 Suppl 1:13-4.
11. Avila M, Prieto P, Robles L, Stosic M, Avila J, Hutton G, et al. Sleep disorders in multiple sclerosis. Int J MS Care. 2010;12 Suppl 1:13.
12. Robles L, Hutton GJ, Rivera VM. Use of natalizumab in Hispanic patients with relapsing remitting multiple sclerosis. Int J MS Care. 2010;12 Suppl 1:58.

13. Thorne BJ, Perez FI, Rivera VM, Hutton GJ. Computer-assisted cognitive rehabilitation for multiple sclerosis — Updated findings. *Int J MS Care.* 2010;12 Suppl 1:69.
14. Uitdehaag B, Constantinescu C, Cornelisse P, Jeffery D, Kappos L, Li D, et al. Associations between annualized relapse rate and long-term exposure to subcutaneous interferon beta-1a in the Prevention of Relapses and disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis (PRISMS) long-term follow-up study. Presented at the European Neurological Society (ENS), 20<sup>th</sup> Annual Meeting in Berlin, Germany (June 19-23, 2010).
15. Hutton G, Avila M, Prieto PG, Avila J, Rivera V. Multiple sclerosis and other CNS demyelination after treatment with tumor necrosis factor alpha blockers. *Neurology.* 2010;74(9 Suppl 2):A371.
16. Bernitsas E, Hutton GJ, Rivera VM. Deep brain stimulation in multiple sclerosis-related Holmes' tremor. *Ann Neurol.* 2009;66 Suppl 1:S40.
17. Herbert J, Rivera V, Ford C, Pace A, Hyde R. Effects of natalizumab on relapses and MRI outcomes in Hispanic patients with relapsing multiple sclerosis. Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 25<sup>th</sup> Congress in Dusseldorf, Germany (Sept. 9-12, 2009).
18. Rivera V, Weinstock-Guttman B, Beagan J, Al-Sabbagh A, Bennett R, Dangond F. Final results from the Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis study. Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 25<sup>th</sup> Congress in Dusseldorf, Germany (Sept. 9-12, 2009).
19. Avila M, Prieto PG, Robles L, Hutton GJ, Rivera VM. Clinical and radiographic improvement of an acutely aggressive case of multiple sclerosis treated with cyclophosphamide. *Int J MS Care.* 2009;11 Suppl 2:S2-3.
20. Avila M, Robles L, Prieto P, Bernitsas E, Stosic M, Hutton GJ, et al. Prevalence of sleep disorders in multiple sclerosis. *Int J MS Care.* 2009;11 Suppl 2:S3.
21. Bernitsas E, Hutton GJ, Rivera VM. Spasmodic dysphonia in MS: A rare symptom or a possible association? *Int J MS Care.* 2009;11 Suppl 2:S1-2.
22. Bernitsas E, Stosic M, Hutton GH, Rivera VM. Seizures in MS patients: A retrospective study. *Int J MS Care.* 2009;11 Suppl 2:S2.
23. Jeffery D, Rivera V. A post-hoc analysis of cumulative dose effects of subcutaneous interferon beta-1a on clinical and MRI outcomes in relapsing-remitting multiple sclerosis: Results over the long term. *Neurology.* 2009;72(11 Suppl 3):A237.
24. Jeffery D, Rivera V. Long-term effects of interferon beta-1a dose on relapse rate in relapsing-remitting multiple sclerosis: Results from a post- hoc analysis of PRISMS study data. *Neurology.* 2009;72(11 Suppl 3):A235-6.
25. Jeffery D, Rivera VM. Long-term sc IFN beta-1a treatment in RRMS: Cumulative dose effects. *Int J MS Care.* 2009;11 Suppl 2:S29-30.
26. Rivera VM, Jeffery D. Continuous vs non-continuous long-term sc IFN beta-1a treatment in RRMS. *Int J MS Care.* 2009;11 Suppl 2:S67.
27. Robles L, Prieto P, DeAlvare L, Hutton GJ, Rivera VM. Diffuse white matter abnormalities and neurologic manifestations in a patient with anti-ro positive antibodies. Case Report. *Int J MS Care.* 2009;11 Suppl 2:S43.
28. Robles L, Prieto P, Rivera VM, Hutton GJ. Occurrence of herpes zoster in multiple sclerosis patients treated with natalizumab. *Int J MS Care.* 2009;11 Suppl 2:S43.
29. Bernitsas E, Hutton GJ, Rivera VM. Marburg's disease and neuromyelitis optica in brother/sister. Presented at the National Multiple Sclerosis Society (NMSS), Tykeson Fellows Conference in Chicago, Ill. (Nov. 4-7, 2008).
30. Avila M, Suarez GA, Brandt D, Ramirez J, Hutton GJ, Rivera VM. Menstrual cycle and menopause in patients with multiple sclerosis. How do these affect the symptoms of disease? *Mult Scler.* 2008;14 Suppl 1:S155.
31. Chaliman RT, Perez FI, Suarez GA, Rivera VM, Hutton GJ. Longitudinal individualized analysis of computer-based cognitive rehabilitation in multiple sclerosis. *Mult Scler.* 2008;14 Suppl 1:S152.
32. Rivera V, Al-Sabbagh A, Bennett R, Coyle P, Elias S, Mikol D, et al. RENEW study update XVIII: Ongoing evaluation of the safety and tolerability of mitoxantrone in worsening multiple sclerosis. *Mult Scler.* 2008;14 Suppl 1:S157.
33. Suarez GA, Avila M, Brandt D, Rivera VM, Hutton GJ. Magnetic resonance imaging findings in patients with clinically isolated syndrome suggestive of multiple sclerosis. *Mult Scler.* 2008;14 Suppl 1:S223.
34. Suarez-Zambrano GA, Ramirez J, Avila M, Brandt D, Escobar BH, Hutton GJ, et al. Silent MRI white matter lesions in patients with CIS suggestive of multiple sclerosis. *Int J MS Care.* 2008;10 Suppl 1:S2.
35. Suarez-Zambrano GA, Pena JA, Avila M, Hutton GJ, Rivera VM. Frequency and severity of restless legs syndrome in multiple sclerosis: A population study from southeast Texas. *Neurology.* 2008;70(11 Suppl 1):A334.
36. Avila M, Ramirez J, Suarez-Zambrano GA, Hutton GJ, Rivera VM. Multiple sclerosis and antiphospholipid syndrome: Case report. Presented at the Mexican Academy of Neurology, 31<sup>st</sup> Annual Meeting in Monterrey, Mexico (Oct. 31 - Nov. 5, 2007).
37. Avila M, Suarez-Zambrano GA, Ramirez J, Hutton GJ, Rivera VM. Encefalomielitis diseminada recurrente y multifásica reporte de 2 casos. Presented at the Mexican Academy of Neurology, 31<sup>st</sup> Annual Meeting in Monterrey, Mexico (Oct. 31 - Nov. 5, 2007). [Recurrent Disseminated Encephalomyelitis: Report of 2 Cases]

38. Suarez-Zambrano GA, Escobar BH, Avila M, Ramirez J, Hutton GJ, Rivera VM. Experience with natalizumab in a group of ms patients from southeast Texas. Presented at the Mexican Academy of Neurology, 31<sup>st</sup> Annual Meeting in Monterrey, Mexico (Oct. 31 - Nov. 5, 2007).
39. Hutton GJ, Avila M, Suarez-Zambrano GA, Ramirez J, Rivera VM. Recurrent disseminated encephalomyelitis: Report of 2 cases. Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 23<sup>rd</sup> Congress in Prague, Czech Republic (Oct. 11-14, 2007).
40. Hutton GJ, Suarez-Zambrano GA, Jafree I, Landero S, Avila M, Rivera VM. Is restless legs syndrome more frequent and severe in the multiple sclerosis population? Study in multiple sclerosis patients from southeast Texas. Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 23<sup>rd</sup> Congress in Prague, Czech Republic (Oct. 11-14, 2007).
41. Suarez-Zambrano GA, Avila M, Landero S, Jafree I, Escobar BH, Ramirez J, et al. Experiencia con natalizumab en 40 pacientes con esclerosis multiple exacerbacion remision. Presented at the Colombian Academy of Neurology, VIII Meeting in Cali, Colombia (Aug. 16-19, 2007).
42. Jafree I, Hashmi K, Landero S, Suarez G, Hutton GJ, Rivera VM. Multiple sclerosis and other autoimmune diseases. *Int J MS Care.* 2007;9(2):65.
43. Landero S, Rivera VM, Hutton GJ, Suarez-Zambrano GA, Ramirez J. Behavior of multiple sclerosis during pregnancy and after delivery. *Int J MS Care.* 2007;9(2):67.
44. Suarez-Zambrano GA, Landero S, Jafree I, Hutton GJ, Rivera VM. Frequency and severity of restless legs syndrome in ms patients from southeast Texas. *Int J MS Care.* 2007;9(2):77.
45. Suarez-Zambrano GA, Landero S, Jafree I, Hutton GJ, Rivera VM. Multiple sclerosis in African Americans: A cohort from southeast Texas. *Int J MS Care.* 2007;9(2):77-8.
46. Suarez-Zambrano GA, Perez F, Avila M, Hutton GJ, Rivera VM. Computer-assisted cognitive rehabilitation in patients with multiple sclerosis. *Int J MS Care.* 2007;9(2):93.
47. Rivera VM, Al-Sabbagh A, Bennett R, Coyle P, Mikol D, Panitch H, et al. Ongoing evaluation of the safety and tolerability of mitoxantrone in worsening multiple sclerosis: The RENEW study. *Neurology.* 2007;68(12 Suppl 1):A275.
48. Suarez-Zambrano GA, Perez F, Avila M, Hutton GJ, Rivera VM. Rehabilitación cognitiva asistida por computadora en pacientes con esclerosis múltiple. *Rev Mex Neuroci.* 2006;7(5):504.
49. Ordoñez L, Skromne E, Rivera-Olmos VM. Caracterizacion de sindromes clinicos de comportamiento similar a esclerosis multiple. *Rev Mex Neuroci.* 2005;6(6):540-1.